Skip to main content
. 2015 Jul 30;5:12633. doi: 10.1038/srep12633

Figure 8. IL-35 administration reverses already established T1D in the NOD mouse model.

Figure 8

(A) NOD mice that had been hyperglycemic (>11.1 mM) for two consecutive days (new-onset diabetic) were treated with PBS (red) or mouse recombinant IL-35 (0.75 μg daily, i.p.) (black) for 8 days as indicated. Blood glucose levels were followed for one month. (B) The percentage of diabetic mice remaining normoglycemic after the treatment with PBS or IL-35, ** denotes p = 0.002. Fisher’s exact test was performed for comparisons on day 5. (C) Representative images of the islets of PBS or IL-35 treated NOD mice. Results are expressed as means ± SEM (n = 6).